Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health Q1 Earnings Call Highlights
Hims & Hers Health NYSE: HIMS reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company's weight-loss business is creating short-term margin pressure and volatility in GAAP results.
Hims & Hers Health: Mixed Q1 2026 Is Not A Thesis Breaker
Hims & Hers Health, Inc. remains a Buy, with a solid bottom forming despite recent margin and revenue challenges. HIMS is pivoting from compounded GLP-1s to branded partnerships with NVO and LLY, impacting near-term margins but reducing legal risk. Q1 2026 saw revenue miss and margin compression, but management raised full-year revenue guidance and expects margin expansion in H2.
Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Misses Revenue Estimates
Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of $0.04. This compares to earnings of $0.2 per share a year ago.
Hims & Hers Stock Sinks. Why Earnings Offered Wall Street A Big Surprise.
Hims & Hers shares are falling after reporting disappointing first-quarter earnings results.
Can Platform Expansion Support Hims & Hers Stock Before Q1 Earnings?
HIMS first-quarter 2026 results are likely to benefit from Labs and branded weight loss medications even as higher costs and GLP-1 scrutiny linger.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Hims & Hers Health, Inc. (HIMS) closed at $26.37 in the latest trading session, marking a -3.79% move from the prior day.
Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HIMS vs. TDOC: Which Digital Health Stock Offers Better Upside Now?
Hims & Hers and Teladoc Health are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.
Hims & Hers Health, Inc. (HIMS) is a Top-Ranked Momentum Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $29.39, representing a -3.83% change from its previous close.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point?
Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement.
